Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
3i, LP
organization5 mentionslast seen Nov 9, 2026
Investment firm that entered into a securities purchase agreement with Valion Bio.
Relationships 4
Relationship
3i, LPinvests inValion Bio, Inc.
99% confidence2 supporting mentionsfrom Apr 29, 2025
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 27, 2026Valion Bio, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 3.02: Unregistered Sales of Equity Securities; Item 9.01: Financial Statements and Exhibits
3i, LP ("3i") are party to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025, the "Series B Preferred Purchase Agreement"), with respect to the purchase and sale of (a) up to 8,400 shares of the Company's Series B Non-Voting Convertible Preferred Stock
- filingSEC EDGAROct 8, 2026Valion Bio, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 3.02: Unregistered Sales of Equity Securities; Item 9.01: Financial Statements and Exhibits
Valion Bio, Inc., a Delaware corporation (the "Company"), and 3i, LP ("3i") are parties to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025, the "Series B Preferred Purchase Agreement"), with respect to the purchase and sale of (a) up to 8,400 shares of the Company's Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Shares") and (b) warrants ("Series B Warrants")